

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Taimei

太美医疗科技

Zhejiang Taimei Medical Technology Co., Ltd.

浙江太美醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2576)

CHANGE OF GENERAL MANAGER

The board (the “**Board**”) of directors (each a “**Director**”) of Zhejiang Taimei Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that due to work re-arrangement, Mr. ZHAO Lu (趙璐) (“**Mr. Zhao**”), an executive Director, the chairman of the Board and the general manager of the Company, ceased to serve as the general manager of the Company with effect from February 11, 2025. Mr. Zhao has confirmed that he has no disagreement with the Board, and there is no matter relating to his resignation as the general manager of the Company that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Mr. Zhao will continue to serve as an executive Director and the chairman of the Board, primarily responsible for overall strategic planning and execution of the Group and development of the Group’s overseas business, and will remain as one of the controlling shareholders of the Company (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

On February 11, 2025, the Board resolved to appoint Ms. WAN Yunyun (萬韞鋆) (“**Ms. Wan**”) as the general manager of the Company with effect from February 11, 2025. Details of Ms. Wan, which are required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, are set out as follows:

Ms. WAN Yunyun (萬韞鋆), aged 40, joined the Group in February 2016 as a vice president of the business development division of the Company. Between October 2019 to June 2023, Ms. Wan was the president of the business-to-business division of the Company. Since June 2023, she has been the president of the digital services division, a senior vice president and the chief commercial officer of the Company. Ms. Wan is also currently the general manager of a subsidiary of the Company, Shanghai Taimei Xingyun Digital Technology Co., Ltd.* (上海太美星雲數字科技有限公司). She is primarily responsible for management and operation of the digital services division of the Group.

Ms. Wan has more than 15 years of experience in the pharmaceutical and medical science industries. Prior to joining the Group, from July 2005 to March 2006, she was an electronic engineer at Compal Electronics Technology (Kunshan) Co., Ltd.* (仁寶電子科技(崑山)有限公司), a company principally engaged in manufacturing of electronic devices, where she was primarily responsible for providing assistance in research. From March 2006 to July 2009, she was a client manager at Shanghai Betterway Marketing Services Co., Ltd.* (上海百達輝琪營銷服務有限公司), a company principally engaged in provision of advertising services, where she was primarily responsible for project management. From September 2009 to February 2016, she was a vice president of business development and a supervisor of Shanghai Jsurre Health Technology Co., Ltd.* (上海捷信醫藥科技股份有限公司), a digital patient solution provider in the pharmaceutical industry, where she was primarily responsible for sales of products to enterprises.

Ms. Wan graduated with a major in public relations from Fudan University (復旦大學) in Shanghai in January 2010. She obtained her master's degree in business administration from Fudan University in Shanghai in January 2020 and her master's degree in business administration from China Europe International Business School (中歐國際工商學院) in Shanghai in November 2023. Ms. Wan further obtained her executive master of business administration in hospitality jointly from China Europe International Business School in Shanghai and EHL Hospitality Business School in Switzerland in April 2024.

Save as disclosed above, as at the date of this announcement, Ms. Wan does not hold any other positions with the Group, nor did she hold any other directorships in the last three years in public companies the securities of which are listed on any securities markets in Hong Kong or overseas, major appointments or professional qualifications. Further, as at the date of this announcement, Ms. Wan has no relationship with any other Directors, supervisors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company, nor does she have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Ms. Wan will serve as the general manager of the Company, primarily responsible for daily management and operation of the Group, for a term commencing on February 11, 2025 and ending on the expiration of the term of the current session of the Board, and may be re-appointed in accordance with the articles of association of the Company. As the general manager, the president of the digital services division, a senior vice president and the chief commercial officer of the Company, Ms. Wan is entitled to receive a monthly salary of RMB106,666, as well as discretionary bonuses, contributions to pension plans, share-based payments, other social security costs, housing benefits and other employee benefits in accordance with her employment contract, which is determined with reference to her background, qualifications, experience, duties and responsibilities with the Group and the prevailing market conditions.

Save as disclosed above, to the best knowledge of the Directors, as at the date of this announcement, there is no other matter in relation to the appointment of Ms. Wan as the general manager of the Company that needs to be brought to the attention of the Shareholders nor any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to congratulate Ms. Wan on her new additional appointment.

* *For identification purpose only*

By Order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Mr. ZHAO Lu
Chairman of the Board

Hong Kong, February 11, 2025

As at the date of this announcement, the Board comprises Mr. ZHAO Lu, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming, Mr. HUANG Yufei and Ms. NI Xiaomei as executive Directors, and Dr. JIANG Xiao, Dr. LI Zhiguo and Mr. FUNG Che Wai Anthony as independent non-executive Directors.